Last updated on August 2019

Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis

Brief description of study

The purpose of this study is to evaluate the efficacy of pimavanserin by comparing pimavanserin with placebo in preventing a relapse of psychotic symptoms in subjects with dementia-related psychosis and who were stabilized after 12 weeks of open label pimavanserin treatment.

Clinical Study Identifier: NCT03325556

Find a site near you

Start Over

ATP Clinical Research Inc.

Costa Mesa, CA United States
  Connect »

Neuro-Pain Medical Center

Fresno, CA United States
  Connect »

Bioclinica Research

Orlando, FL United States
  Connect »

Quantum Laboratories

Pompano Beach, FL United States
  Connect »

Acadia Hospital

Bangor, ME United States
  Connect »

Alzheimer Disease Center

Quincy, MA United States
  Connect »

Precise Research Centers

Flowood, MS United States
  Connect »

Clinical Research Professionals

Chesterfield, MO United States
  Connect »

Neurology Center of Las Vegas

Las Vegas, NV United States
  Connect »

Einstein Clinical, LLC

Phillipsburg, NJ United States
  Connect »

BioBehavioral Health

Toms River, NJ United States
  Connect »

Richmond Behavioral Associates

Staten Island, NY United States
  Connect »

Thomas Jefferson University

Philadelphia, PA United States
  Connect »

BG Neurology LLC

Spartanburg, SC United States
  Connect »

University of Virginia Adult Neurology

Charlottesville, VA United States
  Connect »

AD71, s.r.o.

Praha 10, Czechia
  Connect »

Crystal Comfort, s.r.o.

Vranov nad Toplou, Slovakia
  Connect »